Breaking News
- Teva to Acquire CoGenesys
- Vegenics Licenses From CoGenesys Antibodies Against VEGF-C for Applications Including Oncology
Want to partner
with CoGenesys?
Contact us here.
The Advantages of Albumin Fusion
Results with albumin-fusion proteins already in clinical studies have confirmed the technology's advantages in terms of safety, efficacy and convenience. Albumin fusion technology can also be broadly used for pharmaceuticals with a range of indications, including Cancer, Cardiovascular diseases, Metabolic diseases, Infectious diseases, Autoimmune diseases, and CNS diseases. Drug candidates created using albumin fusion have the potential to increase bio-availability and half-life, reduce dosing and increase safety.
Albumin fusion allows for efficient, scalable and adaptable manufacturing, and the cost of goods for albumin fusion proteins is typically lower than other methods of generating long-acting biopharmaceuticals (e.g. PEGylation, Fc-fusion or chemical cross-linking to albumin).